29 September 2021 - Access to androgen receptor directed therapies, which also have life-prolonging benefits in the castration-resistant prostate cancer setting, varies significantly worldwide. 

Real world data suggest that in countries with access to these agents, for example, within Europe and the United States, their use exceeds that of chemotherapy in the first-line setting for castration-resistant prostate cancer.

For example, access is very limited across the Asian region for financial reasons, and in Australia, until recently, their use is reimbursed only in patients who have received prior chemotherapy or those who are deemed unsuitable for chemotherapy.

Read J Clin Oncol Oncology Practice article